Josh Schimmer is a managing director and senior research analyst who joined Piper Jaffray in 2013 to cover biotechnology companies. Schimmer has been on the Street for more than 10 years; prior to joining Piper Jaffray, he worked in equity research at Lazard Capital Markets, Leerink Swann and Cowen and Company. In addition, he spent time on the buy side at Davidson Kempner as part of the healthcare investing team. Schimmer holds a Doctor of Medicine (MD) from the University of Toronto, where he specialized in Internal Medicine and sub-specialized in Rheumatology. He also holds an MBA from Harvard Business School.